Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
4.310
-0.100 (-2.27%)
Feb 18, 2026, 4:00 PM EST - Market closed
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2024. The number of employees decreased by 3 or -37.50% compared to the previous year.
Employees
5
Change (1Y)
-3
Growth (1Y)
-37.50%
Revenue / Employee
$112,000
Profits / Employee
-$1,759,800
Market Cap
5.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Sep 30, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | 8 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Calidi Biotherapeutics | 28 |
| Theriva Biologics | 22 |
| VivoSim Labs | 14 |
| Purple Biotech | 9 |
| MetaVia | 9 |
| Alzamend Neuro | 7 |
| Mustang Bio | 6 |
| Creative Medical Technology Holdings | 4 |
CANF News
- 2 months ago - Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - GlobeNewsWire
- 2 months ago - Can-Fite Provides Update on Clinical and Financial Status - GlobeNewsWire
- 3 months ago - Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - GlobeNewsWire
- 6 months ago - Can-Fite Reports H1 2025 Financial Results and Clinical Update - GlobeNewsWire
- 7 months ago - Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone - GlobeNewsWire
- 7 months ago - Can-Fite Announces Up To $15.0 Million Public Offering - GlobeNewsWire
- 7 months ago - Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia - GlobeNewsWire
- 11 months ago - Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients - GlobeNewsWire